The regulation and importance of monocyte chemoattractant protein-1

Vanessa Bianconi, Amirhossein Sahebkar, Stephen Atkin, Matteo Pirro

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Purpose of review Monocyte chemoattractant protein (MCP)-1, a chemokine regulating monocyte chemotaxis and T-lymphocyte differentiation by binding to the CC chemokine receptor 2 (CCR2), plays a crucial role in the pathogenesis of inflammatory diseases, atherosclerosis and cancer. This review summarizes the current knowledge on the regulation and importance of the MCP-1/CCR2 axis, focusing on the therapeutic potential of its inhibition. Recent findings Differential modulation of MCP-1 and CCR2 lead to downstream activation pathways, pathogenetic to differing disease conditions characterized by dysregulated monocyte/macrophage tissue recruitment. Pharmacological targeting of the MCP-1/CCR2 axis has led to selective MCP-1/CCR2 antagonists that have now entered phase I/II clinical trials for the treatment of inflammatory diseases, atherosclerosis and cancer. The pleiotropic nonselective MCP-1/CCR2 inhibition by current pharmacological agents is thought to contribute to their anti-inflammatory and antiatherosclerotic effects that is also seen for nutraceutical compounds such as curcumin. Summary MCP-1 has a critical role in regulating chemotaxis both in health and disease, with increasing interest in its pharmacological inhibition. However, the therapeutic efficacy and safety of targeting the MCP-1/CCR2 axis is still in evolution.

Original languageEnglish
Pages (from-to)44-51
Number of pages8
JournalCurrent Opinion in Hematology
Volume25
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

CCR2 Receptors
Chemokine CCL2
Pharmacology
Chemotaxis
Monocytes
Atherosclerosis
Phase II Clinical Trials
Clinical Trials, Phase I
Curcumin
Dietary Supplements
Chemokines
Neoplasms
Anti-Inflammatory Agents
Therapeutics
Macrophages
T-Lymphocytes
Safety
Health

Keywords

  • atherosclerosis
  • cancer
  • CC chemokine receptor 2
  • inflammation
  • monocyte chemoattractant protein

ASJC Scopus subject areas

  • Hematology

Cite this

The regulation and importance of monocyte chemoattractant protein-1. / Bianconi, Vanessa; Sahebkar, Amirhossein; Atkin, Stephen; Pirro, Matteo.

In: Current Opinion in Hematology, Vol. 25, No. 1, 01.01.2018, p. 44-51.

Research output: Contribution to journalReview article

Bianconi, Vanessa ; Sahebkar, Amirhossein ; Atkin, Stephen ; Pirro, Matteo. / The regulation and importance of monocyte chemoattractant protein-1. In: Current Opinion in Hematology. 2018 ; Vol. 25, No. 1. pp. 44-51.
@article{353ea0fa70724cf28286d9e8d2ec32e6,
title = "The regulation and importance of monocyte chemoattractant protein-1",
abstract = "Purpose of review Monocyte chemoattractant protein (MCP)-1, a chemokine regulating monocyte chemotaxis and T-lymphocyte differentiation by binding to the CC chemokine receptor 2 (CCR2), plays a crucial role in the pathogenesis of inflammatory diseases, atherosclerosis and cancer. This review summarizes the current knowledge on the regulation and importance of the MCP-1/CCR2 axis, focusing on the therapeutic potential of its inhibition. Recent findings Differential modulation of MCP-1 and CCR2 lead to downstream activation pathways, pathogenetic to differing disease conditions characterized by dysregulated monocyte/macrophage tissue recruitment. Pharmacological targeting of the MCP-1/CCR2 axis has led to selective MCP-1/CCR2 antagonists that have now entered phase I/II clinical trials for the treatment of inflammatory diseases, atherosclerosis and cancer. The pleiotropic nonselective MCP-1/CCR2 inhibition by current pharmacological agents is thought to contribute to their anti-inflammatory and antiatherosclerotic effects that is also seen for nutraceutical compounds such as curcumin. Summary MCP-1 has a critical role in regulating chemotaxis both in health and disease, with increasing interest in its pharmacological inhibition. However, the therapeutic efficacy and safety of targeting the MCP-1/CCR2 axis is still in evolution.",
keywords = "atherosclerosis, cancer, CC chemokine receptor 2, inflammation, monocyte chemoattractant protein",
author = "Vanessa Bianconi and Amirhossein Sahebkar and Stephen Atkin and Matteo Pirro",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/MOH.0000000000000389",
language = "English",
volume = "25",
pages = "44--51",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The regulation and importance of monocyte chemoattractant protein-1

AU - Bianconi, Vanessa

AU - Sahebkar, Amirhossein

AU - Atkin, Stephen

AU - Pirro, Matteo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose of review Monocyte chemoattractant protein (MCP)-1, a chemokine regulating monocyte chemotaxis and T-lymphocyte differentiation by binding to the CC chemokine receptor 2 (CCR2), plays a crucial role in the pathogenesis of inflammatory diseases, atherosclerosis and cancer. This review summarizes the current knowledge on the regulation and importance of the MCP-1/CCR2 axis, focusing on the therapeutic potential of its inhibition. Recent findings Differential modulation of MCP-1 and CCR2 lead to downstream activation pathways, pathogenetic to differing disease conditions characterized by dysregulated monocyte/macrophage tissue recruitment. Pharmacological targeting of the MCP-1/CCR2 axis has led to selective MCP-1/CCR2 antagonists that have now entered phase I/II clinical trials for the treatment of inflammatory diseases, atherosclerosis and cancer. The pleiotropic nonselective MCP-1/CCR2 inhibition by current pharmacological agents is thought to contribute to their anti-inflammatory and antiatherosclerotic effects that is also seen for nutraceutical compounds such as curcumin. Summary MCP-1 has a critical role in regulating chemotaxis both in health and disease, with increasing interest in its pharmacological inhibition. However, the therapeutic efficacy and safety of targeting the MCP-1/CCR2 axis is still in evolution.

AB - Purpose of review Monocyte chemoattractant protein (MCP)-1, a chemokine regulating monocyte chemotaxis and T-lymphocyte differentiation by binding to the CC chemokine receptor 2 (CCR2), plays a crucial role in the pathogenesis of inflammatory diseases, atherosclerosis and cancer. This review summarizes the current knowledge on the regulation and importance of the MCP-1/CCR2 axis, focusing on the therapeutic potential of its inhibition. Recent findings Differential modulation of MCP-1 and CCR2 lead to downstream activation pathways, pathogenetic to differing disease conditions characterized by dysregulated monocyte/macrophage tissue recruitment. Pharmacological targeting of the MCP-1/CCR2 axis has led to selective MCP-1/CCR2 antagonists that have now entered phase I/II clinical trials for the treatment of inflammatory diseases, atherosclerosis and cancer. The pleiotropic nonselective MCP-1/CCR2 inhibition by current pharmacological agents is thought to contribute to their anti-inflammatory and antiatherosclerotic effects that is also seen for nutraceutical compounds such as curcumin. Summary MCP-1 has a critical role in regulating chemotaxis both in health and disease, with increasing interest in its pharmacological inhibition. However, the therapeutic efficacy and safety of targeting the MCP-1/CCR2 axis is still in evolution.

KW - atherosclerosis

KW - cancer

KW - CC chemokine receptor 2

KW - inflammation

KW - monocyte chemoattractant protein

UR - http://www.scopus.com/inward/record.url?scp=85036547511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036547511&partnerID=8YFLogxK

U2 - 10.1097/MOH.0000000000000389

DO - 10.1097/MOH.0000000000000389

M3 - Review article

VL - 25

SP - 44

EP - 51

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 1

ER -